Clinical Trials Logo

Filter by:
NCT ID: NCT04809558 Completed - Clinical trials for Focus of Study is Tongue Strength

Optimal Method for Tongue Strengthening

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The research team will conduct a multi-site, randomized controlled trial examining the effectiveness of exercise intensity progression compared to standard practice (no progression) in the context of swallowing rehabilitation. The study will also determine the impact of using biofeedback during resistance training on tongue strength. The study is a first step in determining an optimal delivery of tongue strengthening exercise in typically aging older persons, with the plan to develop a framework for guiding clinical practice of tongue strengthening in various dysphagic populations. Participants will be randomized into one of four treatment groups and complete 8 weeks of tongue resistance training.

NCT ID: NCT04809285 Completed - Clinical trials for Type 1 Diabetes Mellitus

Use of the Guardian™ Connect System With Smart Connected Devices

Start date: April 6, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to collect sensor, insulin, sleep, activity and food/meal data for a minimum of 90 days of device wear (Phase 1) and up to a maximum of 9 months of device wear (Phase 2) with optional insulin injection video capture and/or menstrual cycle tracking and/or cardiac monitoring in subjects with insulin requiring diabetes 2-80 years of age.

NCT ID: NCT04809207 Completed - Cystic Fibrosis Clinical Trials

Acceptability, Feasibility and Preliminary Efficacy of CFWP to Treat Clinically Elevated Fatigue in Adults With CF

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

This research is being done to learn more ways to treat non-respiratory symptoms in people with CF including fatigue, pain, mood, sleep problems and the use of a wellness program to treat them.

NCT ID: NCT04809194 Completed - Crohn Disease Clinical Trials

Stress in Crohn's Disease

Start date: September 1, 2019
Phase:
Study type: Observational

There is little information on how Crohn's disease progresses in between a patient's clinic visits and how stress impacts symptom change including flare-ups. The purpose of this research study is to see if digital tools like smartphones, and wearable devices are helpful in finding out new information that may explain fluctuation in symptoms. This study is a feasibility study that will try to identify biomarkers, collected through a smartphone app and wearable devices paired with clinical information collected during clinic visits to track participants' overall health for 6 to 12 months. The data collected will be used to identify and predict symptoms associated with Crohn's disease flare ups. The aim of this work is to inform knowledge of what triggers Crohn's disease worsening that might lead to advances in management.

NCT ID: NCT04809051 Completed - Clinical trials for Cardiac Transplant Disorder

Don't Throw Your Heart Away: Patient Study 4

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This empirical study tests whether transplant center performance data that reflect center donor acceptance rates influence patients and their family members to evaluate centers with high organ decline rates less favorably than centers with low organ decline rates. 400 transplant patients and family members will be recruited from transplant support group social media websites and randomized to one of four different information presentation conditions. Upon viewing a pair of outcome tables corresponding to their condition, the participants are asked to choose which hospital is higher performing (one hospital with a non-selective "accepting" strategy and one hospital with a more selective "cherrypicking" strategy.

NCT ID: NCT04808908 Completed - HIV Infections Clinical Trials

Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease

Start date: April 1, 2021
Phase: Phase 1
Study type: Interventional

N-803 has demonstrated ability to reactivate HIV from latency and can activate T cells and NK cells to clear those cells, thus reducing the reservoir. However, a concern is that CD8 T cells may be excluded from the B cell follicles, where a significant part of the reservoir resides. Webb, et al, has shown that in SIV infected monkeys CD8 T cells in follicles increase in frequency when N-803 is administered. We hypothesize that in HIV infected humans treated with N-803 that CD8 T cells will increase in B cell follicles and that there will be a further reduction in the frequency of cells with an inducible provirus.

NCT ID: NCT04808869 Completed - Clinical trials for Exercise Intervention

Effectiveness of Blood Flow Restriction During Aerobic Cycling

Start date: June 12, 2020
Phase: N/A
Study type: Interventional

Blood flow restriction (BFR) training has become a popular alternate rehabilitation modality, intending to improve muscle strength, hypertrophy, metabolic response, and functional outcomes in diverse populations. However, there is a paucity of research evidence on the effectiveness of using BFR during aerobic exercise. Most BFR interventions have used BFR cuffs in two to four limbs, however, it is unknown if using BFR cuffs in a single limb instead of multiple limbs can produce the desired outcomes in muscle physiology and muscular adaptations. Therefore, we have divided the purpose of this study into the following three aims: Compare physical performance measures of balance, isokinetic muscle strength, knee stability, and aerobic capacity between cycling exercise with and without BFR. Compare physical performance measures between performing cycling exercise at 60% versus 80% blood flow occlusion. Compare physical performance measures between bilateral BFR versus single-leg BFR during a cycling protocol. These aims will be accomplished by randomizing 55 participants into five groups of eleven participants each: 1) control; 2) bilateral BFR cuffs with 60% occlusion; 3) bilateral BFR cuffs with 80% occlusion; 4) single-limb BFR with 60% occlusion; and 5) single-limb BFR with 80% occlusion. All participants will undergo balance, isokinetic knee strength, knee stability, and aerobic testing at baseline, 3-week, and 6-week follow-ups. The intervention for all groups will consist of 15 minutes cycling on a stationary ergometer at 70 revolutions/minute. A within- and between-group (5) by time (3) repeated measures analysis of variance (ANOVA) will be used to explore differences between group and time in addition to the interaction between these two.

NCT ID: NCT04808622 Completed - Healthy Subjects Clinical Trials

Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers

Start date: March 17, 2021
Phase: Phase 1
Study type: Interventional

Randomized, double-blind, placebo-controlled, pharmacokinetic, pharmacodynamic study. Subjects will be randomized to TSC or placebo to determine the effect of Trans Sodium Crocetinate (TSC) on Transcutaneous Oximetry Measurements (tcpO2) following a single administration of TSC in subjects breathing oxygen (O2).

NCT ID: NCT04808609 Completed - Hiv Clinical Trials

Smoking Cessation Pilot for People Living With HIV (PLWH)

Start date: October 6, 2020
Phase: N/A
Study type: Interventional

The overall goal of this pilot study is to evaluate the feasibility of the Lumme smartphone app for smoking cessation in people living with HIV (PLWH) and evaluate its effect on smoking cessation. Mobile health (mHealth) technology can be used for achieving health equity in vulnerable groups because it is a widely available and relatively inexpensive tool for health behavior change and can be adapted to meet the needs of its end-users. Therefore, a mHealth intervention such as the Lumme App proposed through this study is timely, relevant, scalable and likely to improve health outcomes in PLWH who smoke.

NCT ID: NCT04808453 Completed - Advanced Tumors Clinical Trials

Phase I Study of CPI-300 in Patients With Advanced Tumors

CPI-300
Start date: June 15, 2021
Phase: Phase 1
Study type: Interventional

This is a prospective, open-label, single arm, non-randomized study of CPI-300 in patients with advanced tumors. CPI-300 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD).